



FOR IMMEDIATE RELEASE

September 28, 2009

Breckenridge Announces Approval of Cilostazol Tablets®

Boca Raton, Florida, September 28, 2009 – Breckenridge Pharmaceutical, Inc. announced today that the U.S. Food and Drug Administration has granted final approval for the Company's Abbreviated New Drug Application (ANDA) for Cilostazol Tablets, USP, 50mg and 100mg. Cilostazol Tablets are AB rated to Pletal®, a brand product marketed by Otsuka America Pharmaceutical, Inc. The product launch plans are still being finalized.

About Breckenridge:

Breckenridge Pharmaceutical is a privately held pharmaceutical marketing, research and development company founded in 1983 that markets a broad range of ValuBrand™ and Generic prescription products in many therapeutic categories. The Breckenridge label is recognized by Wholesalers, Distributors, Chains, and Managed Care Accounts, as well as Retail Pharmacies nationwide. The company markets over 100 products, including multiple ANDA's, in a variety of dosage forms including: Tablets, Capsules, Soft Gel Capsules, Liquids, Suspensions and Topical preparations. www.bpirx.com

For Further Information, please contact:

Breckenridge Pharmaceutical

Larry Lapila, Vice President Business Development

TEL: 860-828-8140 FAX: 860-828-8142

e-Mail: llapila@bpirx.com